UK Markets close in 7 hrs 48 mins

Biophytis SA (0D1W.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.9700+2.1578 (+265.69%)
As of 4:56PM BST. Market open.
Full screen
Previous close0.8122
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.8122 - 0.8122
52-week range0.8122 - 0.8122
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)1.14
PE ratio (TTM)N/A
EPS (TTM)-0.2840
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Biophytis Reports H1 2021 Financial Results and Provides Business Update

    SARA-INT: Positive top line results of Phase 2 study demonstrate efficacy of Sarconeos (BIO101) in sarcopenia and support progress into Phase 3COVA: DMC second interim analysis shows efficacy results in the promising zone allowing continuation of the phase 2/3 study with Sarconeos (BIO101) in COVID-19. Top line results of the full study are expected in Q1 2022Manufacturing scale up signed with a major global CDMO to increase potential supply of Sarconeos (BIO10) in anticipation of COVA positive

  • Globe Newswire

    Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19

    The independent DMC (Data Monitoring Committee) recommends continuation of Part 2 of the Phase 2-3 Study (“the COVA Study”) without any protocol amendmentThe second Interim Analysis (“IA2”) based on 155 hospitalized patients shows no futility, with efficacy results in the promising zone, indicating that BIO101 remains a candidate treatment for acute respiratory failure associated with COVID-19 To date, 200 patients have been enrolled in COVA study and 15 additional sites in USA, Brazil, France,

  • Globe Newswire

    Biophytis to Attend Key Upcoming Investor Events and Industry Conferences

    PARIS and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces its management will participate and meet with investors at the